All In Biotech

Free tool

FAERS Monitor: Padcev

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761137 or its brand name (Padcev, Enfortumab Vedotin-Ejfv). Reports on generic versions are filed under their own applications.

Reports

7,851

Serious

6,925

88% of reports

Hospitalization

2,685

Death reported

1,561

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash1,019
  • neuropathy peripheral909
  • malignant neoplasm progression893
  • diarrhoea503
  • pruritus467
  • death436
  • decreased appetite424
  • fatigue423
  • off label use362
  • alopecia324
  • skin disorder314
  • pyrexia313
  • nausea290
  • hyperglycaemia276
  • taste disorder265

Reports by year received

View as table
YearReports
20172
20181
2020221
2021328
2022877
2023951
20241,165
20252,438
20261,868

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,308 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
taste disorderSignal26535.431.58,729
neuropathy peripheralSignal90925.824.321,569
skin disorderSignal31425.522.87,295
malignant neoplasm progressionSignal89323.622.119,192
hyperglycaemiaSignal27620.418.25,054
rashSignal1,0196.35.94,598
decreased appetiteSignal4244.94.51,323
alopeciaSignal3244.44.0862
pruritusSignal4673.33.0741
pyrexiaSignal3132.42.2265
diarrhoeaSignal5032.11.9293
fatigue4231.51.362
death4361.41.242
off label use3621.11.04
nausea2901.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.